<DOC>
	<DOCNO>NCT00001239</DOCNO>
	<brief_summary>To evaluate dose intensive chemotherapy regimen treatment locally advance metastatic breast cancer use granulocyte-macrophage colony-stimulating factor ( GM-CSF ) ameliorate chemotherapy-induced toxicity . Combination chemotherapy consist Flurouricil , Leucovorin , Adriamycin , Cytoxan ( FLAC ) give every 21 day 10 cycle . This protocol replace phase I study regimen ( MB-232/88-C-0207 ) find MTD regimen first dose level . This phase II study determine response rate regimen advanced breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy ( FLAC ) Combined With Granulocyte-Macrophage Colony Stimulating Factor Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>To evaluate dose intensive chemotherapy regimen treatment locally advance metastatic breast cancer use granulocyte-macrophage colony-stimulating factor ( GM-CSF ) ameliorate chemotherapy-induced toxicity . Combination chemotherapy consist Flurouricil , Leucovorin , Adriamycin , Cytoxan ( FLAC ) give every 21 day 10 cycle . This protocol replace phase I study regimen ( MB-232/88-C-0207 ) find MTD regimen first dose level . This phase II study determine response rate regimen advanced breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>All stage III clinical T3N0 TxN2 patient must histologically document diagnosis breast carcinoma evaluate disease breast axilla . Patients stage III must enter protocol within 12 week initial diagnosis . Patients Stage IV ( metastatic ) breast cancer must histologically prove diagnosis must evaluate disease . Patients boneonly disease may consider eligible discussion Dr. Kenneth Cowan . For Stage III disease , must history prior cytotoxic therapy . Stage IV patient eligible prior adjuvant chemotherapy and/or hormonal therapy provide regimen include adriamycin . Patients also eligible treat one prior Phase I II single chemotherapy agent Medicine branch protocol . Patients prior radiation therapy may eligible provide extensive radiation cardiac area . There must history previous malignancy except cured nonmelanoma skin cancer ( basal cell carcinoma ) cervical cancer situ . Performance status ( Karnofsky scale ) must great 70 . WBC count great 4000/mm3 platelet count 100,000/mm3 , unless evidence bone marrow involvement tumor . Liver function test ( SGOT , Alk . Phosph. , T. Bilil ) less 1.5 time upper limit normal , serum creatinine le 1.7 creatinine clearance great 45 ml/min unless abnormality due tumor involvement . The patient must give informed consent . No pregnant patient may enter study ; patient inform need contraception . No history malignant neoplasms except curatively treat basal cell skin cancer surgically cure carcinoma cervix situ . Patients must poor medical psychiatric risk nonmalignant systemic disease would preclude subjected treatment protocol . Patients history cardiac disease must normal ejection fraction MUGA Scan angina . Must evidence CNS metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>5-Fluorouracil</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Breast Carcinoma</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Phase II</keyword>
</DOC>